Major Announcements - Guotai Group acquired 100% equity of Beikuan Baomao for 110 million yuan through public bidding [3] - People's Tongtai stock price has risen for four consecutive trading days, with a total increase of 46.43%, indicating potential rapid decline risk due to market sentiment [4] - Huasheng Lithium's stock price has deviated significantly, with a 62% revenue increase in the first three quarters, but still reporting a net loss of 10.3 million yuan [5] - Haishi Ke received approval for clinical trials of innovative drug HSK39297 for age-related macular degeneration, showing high development potential [6] - Angli Education postponed its response to an asset acquisition inquiry for no more than five trading days [7] - Shuguang Co. terminated its plan to issue shares to specific targets, with the Shanghai Stock Exchange halting the review [8] Performance Overview - JD Group reported third-quarter revenue of 299.1 billion yuan, a year-on-year increase of 14.9%, with net profit of 5.3 billion yuan [10] - SMIC achieved third-quarter net profit of 1.517 billion yuan, a 43.1% year-on-year increase, with revenue of 17.162 billion yuan [11][12] - Tencent Holdings reported third-quarter revenue of 192.87 billion yuan, a 15% year-on-year increase, with operating profit of 72.57 billion yuan [13] - Lu'an Huaneng's coal sales in October reached 3.78 million tons, a year-on-year increase of 3.28% [14] Shareholding Changes - Haicheng Bangda's director Wang Xiping plans to reduce his holdings by up to 0.97% due to personal financial needs [16] - Qisheng Technology's major shareholder reduced their stake to 40% through a block trade [17] - Tianwei Electronics' major shareholder Xie Kai reduced his holdings to below 5% [18] - Zhongzi Technology's major shareholders collectively reduced their stake by 1.35% [19] Major Contracts - Lichong Group's subsidiaries received project confirmations with an estimated total sales of approximately 1.135 billion yuan [21] - Anhui Construction's subsidiary won a project bid worth 1.753 billion yuan [22]

证券代码：002653 证券简称：海思科 公告编号：2025-124 海思科医药集团股份有限公司 关于 2024 年限制性股票激励计划第一个解除限售期 解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次符合解除限售条件的激励对象共计 6 人，本次解除限售 的限制性股票数量为 1,740,000 股，占目前公司总股本的 0.1554%。 2、本次解除限售的限制性股票的上市流通日期为 2025 年 11 月 19 日。 海思科医药集团股份有限公司（以下简称"公司"）于 2025 年 11 月 7 日召开的第五届董事会第三十二次会议，审议通过了《关于 2024 年限制性股票激励计划第一个解除限售期解除限售条件成就的 议案》，公司 2024 年限制性股票激励计划第一个解除限售期解除限 售条件已经成就。根据公司 2024 年第一次临时股东大会对董事会的 授权，公司办理了 2024 年限制性股票激励计划第一个解除限售期股 份上市流通手续，本次符合解除限售条件的激励对象共计 6 人，本次 解除限售的限制性股票数量为 1,7 ...

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

Core Viewpoint - The company, Haishi Ke (002653), has received approval from the National Medical Products Administration for its new drug HSK39297, aimed at treating age-related macular degeneration (AMD) [1] Group 1: Drug Development - HSK39297 is a novel drug developed independently by the company, possessing its own intellectual property rights [1] - Preclinical research indicates that the drug has a clear target, confirmed efficacy, and good safety profile, making it a promising small molecule drug [1] - The drug is expected to have a high benefit/risk ratio in clinical applications, indicating its potential for successful treatment outcomes [1] Group 2: Market Potential - The approval of HSK39297 addresses the current shortage of effective clinical treatments for AMD, highlighting its broad clinical application prospects [1] - The drug is anticipated to become an effective treatment option for AMD, which is a significant unmet medical need in the market [1]

证券代码：002653 证券简称：海思科 公告编号：2025-123 海思科医药集团股份有限公司 关于获得创新药 HSK39297 片新适应症 《药物临床试验批准通知书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）近日收到国 家药品监督管理局下发的《药物临床试验批准通知书》，现将相关情 况公告如下： | 药品名称 | | 剂型 | 适应症 | 申请事项 | 受理号 | | --- | --- | --- | --- | --- | --- | | HSK39297 | 片 | 片剂 | 年龄相关性 | 境内生产药品 | CXHL2500852 | | | | | 黄斑变性 | 注册临床试验 | CXHL2500853 | 根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 8 月受理的 HSK39297 片临床试验申请符合药品注册的有关要求， 同意本品开展临床试验。 一、 研发项目简介 年龄相关性黄斑变性（age-related macular degeneration，AMD） 是视网膜 ...

Core Viewpoint - The company received approval from the National Medical Products Administration for clinical trials of its innovative drug HSK39297 tablets, aimed at treating age-related macular degeneration, indicating a significant advancement in its product pipeline [1] Group 1: Drug Development - HSK39297 is a tablet formulation specifically targeting age-related macular degeneration [1] - Preclinical studies have shown that HSK39297 has a clear target, confirmed efficacy, and good safety profile, suggesting a high benefit/risk ratio [1] - The drug is expected to offer a more advantageous treatment option compared to existing therapies, which often require frequent injections and do not significantly improve vision [1] Group 2: Market Potential - There are currently limited treatment options available for age-related macular degeneration, highlighting the potential market opportunity for HSK39297 [1] - The approval for clinical trials positions the company favorably within a niche market with significant unmet medical needs [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its innovative drug HSK39297, aimed at treating age-related macular degeneration (AMD) [1] Company Summary - HSK39297 is an innovative drug developed by the company, specifically targeting age-related macular degeneration [1] - The drug has a clear target, proven efficacy, and good safety profile, which may address existing challenges in clinical treatment options for AMD [1] Industry Summary - In 2015, the prevalence of AMD in China was approximately 5.2%, affecting nearly 26.65 million people, with projections indicating nearly 300 million cases by 2040 [1] - Current treatment options for AMD are limited, highlighting the potential market opportunity for new therapies like HSK39297 [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of HSK39297 tablets, a new drug for age-related macular degeneration (AMD) with independent intellectual property rights [1] Group 1: Drug Development - HSK39297 tablets are independently developed by the company and target age-related macular degeneration [1] - Preclinical research indicates that the drug has a clear target, definite efficacy, and good safety profile, making it a promising small molecule drug [1] - The drug is expected to have a high benefit/risk ratio in clinical applications, indicating a broad clinical application prospect [1] Group 2: Market Potential - HSK39297 tablets aim to address the current shortage of effective clinical treatments for AMD, potentially becoming a viable therapeutic option [1]

证券代码：002653 证券简称：海思科 公告编号：2025-122 海思科医药集团股份有限公司 关于控股股东部分股份质押展期及解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）于近日接到 公司控股股东及实际控制人王俊民先生的通知，获悉王俊民先生所持 有本公司的部分股份质押展期及解除质押，具体事项如下： 1 股东 名称 是否为控 股股东或 第一大股 东及其一 致行动人 本次质押 数量 (万股) 占其 所持 股份 比例 占公 司总 股本 比例 是否 为限 售股 是否 为补 充质 押 原质 押起 始日 原质 押到 期日 展期后 到期日 质权 人 质押 用途 王俊民 是 234 0.59% 0.21% 否 否 2024 年 11 月 11 日 2025 年 11 月 11 日 2026 年 11 月 11 日或质权 人办理完毕 解除质押登 记手续之日 中信 证券 股份 有限 公司 自身 生产 经营 合计 - 234 0.59% 0.21% - - - - - - - 一、股东股份质押展期的基本情况 二、股东 ...

海思科公告称，控股股东及实控人王俊民部分股份质押展期及解除质押。质押展期方面，234万股质押 到期日由2025年11月11日展至2026年11月11日或质权人办理解除质押登记手续之日，占其所持股份 0.59%，占公司总股本0.21%，用途为自身生产经营。解除质押方面，303万股于2025年11月11日到期解 除质押，占其所持股份0.76%，占公司总股本0.27%。截至公告披露日，王俊民及其一致行动人累计质 押股份7094万股，占其所持股份16.13%，占公司总股本6.33%。 ...